Equities

DNA Chip Research Inc

2397:TYO

DNA Chip Research Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)694.00
  • Today's Change-8.00 / -1.14%
  • Shares traded13.40k
  • 1 Year change-2.94%
  • Beta1.9369
Data delayed at least 20 minutes, as of Nov 22 2024 05:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year DNA Chip Research Inc grew revenues 49.74% from 327.54m to 490.46m while net income improved from a loss of 362.34m to a smaller loss of 248.29m.
Gross margin38.52%
Net profit margin-15.41%
Operating margin-16.85%
Return on assets-14.12%
Return on equity-18.91%
Return on investment-17.74%
More ▼

Cash flow in JPYView more

In 2024, DNA Chip Research Inc increased its cash reserves by 41.05%, or 113.05m. Cash Flow from Financing totalled 269.05m or 54.86% of revenues. In addition the company used 140.23m for operations while cash used for investing totalled 15.78m.
Cash flow per share-10.69
Price/Cash flow per share--
Book value per share103.64
Tangible book value per share85.58
More ▼

Balance sheet in JPYView more

DNA Chip Research Inc has little financial risk as the capital structure does not rely on leverage.
Current ratio3.07
Quick ratio2.78
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.